Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GenMark Diagnostics Inc. GNMK

Healthcare
GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary... see more

Recent & Breaking News (NDAQ:GNMK)

GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum

GlobeNewswire November 5, 2020

GenMark Diagnostics Reports Third Quarter 2020 Results

GlobeNewswire October 28, 2020

GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020

GlobeNewswire October 14, 2020

GenMark Diagnostics' ePlex® Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA

GlobeNewswire October 8, 2020

GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020

GlobeNewswire October 8, 2020

Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments

PR Newswire September 22, 2020

GenMark Diagnostics' ePlex® Respiratory Pathogen Panel 2 (RP2) achieves CE Mark

GlobeNewswire September 14, 2020

GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor® SARS-CoV-2 Test

GlobeNewswire August 17, 2020

GenMark Diagnostics Reports Second Quarter 2020 Results

GlobeNewswire August 4, 2020

GenMark Diagnostics to Participate in Upcoming Investor Conferences

GlobeNewswire July 29, 2020

GenMark Diagnostics to Report Second Quarter 2020 Financial Results on August 4, 2020

GlobeNewswire July 21, 2020

GenMark Diagnostics Provides Preliminary Financial and Operational Results for Second Quarter 2020

GlobeNewswire July 7, 2020

GenMark Diagnostics Announces Commercial Launch of its ePlex® Respiratory Pathogen Panel 2 (RP2)

GlobeNewswire June 29, 2020

GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Health

GlobeNewswire June 16, 2020

GenMark Diagnostics to Participate in Upcoming Investor Conferences

GlobeNewswire May 27, 2020

GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire May 11, 2020

GenMark Prices Public Offering of Common Stock

GlobeNewswire May 6, 2020

GenMark Commences Public Offering of Common Stock

GlobeNewswire May 6, 2020

GenMark Diagnostics Reports First Quarter 2020 Results

GlobeNewswire May 4, 2020

GenMark Diagnostics Announces Scott Mendel Appointed CEO

GlobeNewswire May 4, 2020